These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 24277729

  • 1. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN).
    Das KK, Xiao H, Geng X, Fernandez-Del-Castillo C, Morales-Oyarvide V, Daglilar E, Forcione DG, Bounds BC, Brugge WR, Pitman MB, Mino-Kenudson M, Das KM.
    Gut; 2014 Oct; 63(10):1626-34. PubMed ID: 24277729
    [Abstract] [Full Text] [Related]

  • 2. Cytology adds value to monoclonal antibody Das-1 testing for detection of high-risk pancreatic cysts.
    Heidarian A, Das KK, Mino-Kenudson M, Fernandez-Del Castillo C, Pitman MB.
    J Am Soc Cytopathol; 2021 Oct; 10(3):249-254. PubMed ID: 33541830
    [Abstract] [Full Text] [Related]

  • 3. Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions.
    Das KK, Geng X, Brown JW, Morales-Oyarvide V, Huynh T, Pergolini I, Pitman MB, Ferrone C, Al Efishat M, Haviland D, Thompson E, Wolfgang C, Lennon AM, Allen P, Lillemoe KD, Fields RC, Hawkins WG, Liu J, Castillo CF, Das KM, Mino-Kenudson M.
    Gastroenterology; 2019 Sep; 157(3):720-730.e2. PubMed ID: 31175863
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
    Morimatsu K, Aishima S, Yamamoto H, Hayashi A, Nakata K, Oda Y, Shindo K, Fujino M, Tanaka M, Oda Y.
    Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, Shibata N, Shimizu M, Furukawa T.
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A, Arisaka Y, Hara S, Matsumoto I, Takenaka M, Sakai A, Shiomi H, Matsuki N, Sugimoto M, Fujita T, Hayakumo T, Ku Y, Ogino S, Azuma T, Kutsumi H.
    Pancreatology; 2013 Nov; 13(6):583-8. PubMed ID: 24280573
    [Abstract] [Full Text] [Related]

  • 10. Thirty years of experience with intraductal papillary mucinous neoplasm of the pancreas: from discovery to international consensus.
    Tanaka M.
    Digestion; 2014 Nov; 90(4):265-72. PubMed ID: 25591885
    [Abstract] [Full Text] [Related]

  • 11. mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy.
    Das KK, Brown JW, Fernandez Del-Castillo C, Huynh T, Mills JC, Matsuda Y, Das KM, Mino-Kenudson M.
    Hum Pathol; 2021 May; 111():36-44. PubMed ID: 33524436
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D, Damaskos C, Spartalis E, Papalampros A, Vernadakis S, Dimitroulis D, Griniatsos J, Felekouras E, Nikiteas N.
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [Abstract] [Full Text] [Related]

  • 15. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S, Klauss M, Bergmann F, Strobel O, Schneider L, Werner J, Hackert T, Büchler MW.
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [Abstract] [Full Text] [Related]

  • 16. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
    Simpson RE, Yip-Schneider MT, Flick KF, Wu H, Colgate CL, Schmidt CM.
    Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
    Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kobayashi S, Kojima M, Miyauchi H, Asano T.
    J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.